1. Home
  2. CALC vs INKT Comparison

CALC vs INKT Comparison

Compare CALC & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CALC
  • INKT
  • Stock Information
  • Founded
  • CALC 2011
  • INKT 2017
  • Country
  • CALC United States
  • INKT United States
  • Employees
  • CALC N/A
  • INKT N/A
  • Industry
  • CALC Biotechnology: Pharmaceutical Preparations
  • INKT Medicinal Chemicals and Botanical Products
  • Sector
  • CALC Health Care
  • INKT Health Care
  • Exchange
  • CALC Nasdaq
  • INKT Nasdaq
  • Market Cap
  • CALC 36.0M
  • INKT 36.7M
  • IPO Year
  • CALC N/A
  • INKT 2021
  • Fundamental
  • Price
  • CALC $2.51
  • INKT $9.50
  • Analyst Decision
  • CALC Strong Buy
  • INKT Strong Buy
  • Analyst Count
  • CALC 5
  • INKT 2
  • Target Price
  • CALC $18.20
  • INKT $6.50
  • AVG Volume (30 Days)
  • CALC 32.4K
  • INKT 72.8K
  • Earning Date
  • CALC 03-27-2025
  • INKT 03-20-2025
  • Dividend Yield
  • CALC N/A
  • INKT N/A
  • EPS Growth
  • CALC N/A
  • INKT N/A
  • EPS
  • CALC N/A
  • INKT N/A
  • Revenue
  • CALC N/A
  • INKT N/A
  • Revenue This Year
  • CALC N/A
  • INKT N/A
  • Revenue Next Year
  • CALC N/A
  • INKT N/A
  • P/E Ratio
  • CALC N/A
  • INKT N/A
  • Revenue Growth
  • CALC N/A
  • INKT N/A
  • 52 Week Low
  • CALC $2.05
  • INKT $4.56
  • 52 Week High
  • CALC $6.27
  • INKT $19.00
  • Technical
  • Relative Strength Index (RSI)
  • CALC 39.62
  • INKT 52.27
  • Support Level
  • CALC $2.37
  • INKT $8.85
  • Resistance Level
  • CALC $2.75
  • INKT $13.79
  • Average True Range (ATR)
  • CALC 0.22
  • INKT 1.93
  • MACD
  • CALC 0.00
  • INKT -0.07
  • Stochastic Oscillator
  • CALC 26.17
  • INKT 53.50

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapies for life-threatening inflammatory diseases with high unmet need. Its proprietary technology targets the inhibition of calcium release-activated calcium channels designed to modulate the immune response and protect against tissue cell injury, with the potential to provide therapeutic benefits in life-threatening inflammatory diseases for which there are no approved therapies.

About INKT MiNK Therapeutics Inc.

MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing allogeneic invariant natural killer T-cell therapies to treat cancer and other life-threatening illnesses.

Share on Social Networks: